RNASE4

Across TCGA pan-cancer cohorts, RNASE4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RNASE4 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNASE4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where RNASE4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.454	0.877	<.001	48	view →
CCRCC	OS	Median	II,III,IV	0.339	1.000	.003	32	view →
GBM	DFS	Median	All	0.632	0.863	.003	16	view →
LSCC	DFS	Tertile	II,III,IV	0.830	1.000	.017	12	view →
PDAC	OS	Tertile	II,III,IV	0.377	0.599	.043	4	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNASE4–LUAD (OS)

Open the LUAD breakdown →